This is a working overview of peptide analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-06 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
There has yet to be any academic evidence for the idea that there were significant forces considered loyal to the old regime. Rather, the continued fighting which was seen after the flight of Ceaușescu is believed to have been a result of mistaken exchanges of fire from the general population and armed forces. There has been no academic evidence to suggest that Securitate units fought against the revolution. The origins of this story can be found in the speech given on 22 December by Army Captain Mihail Lupoi. During this speech, he asserts that it was only the Securitate who had shot protesters before the 22nd and that the Securitate needs to come onto the side of the army. This placed the deaths of protesters by the army onto the shoulders of the Securitate. But both the army and Securitate had shot and killed protesters before the 22nd. The vast majority of deaths came from the period between 22 and 25 December. On the 22nd, a small group of individuals which would later comprise the core of the National Salvation Front (Romanian: Frontul Salvării Naționale, FSN), called for a mass mobilisation of people for the defence of the television station. This call to arms resulted in the accumulation of army personnel, patriotic guards (both in and out of uniform) and armed civilians guarding the station. Later the same evening, there was an announcement that a convoy of anti-terrorist units were heading for the television centre. This was not so, but it added to the extremely tense environment which had been building since the flight of Ceaușescu.
Traditional balance of power theory … fails to explain state behavior in the post-Cold War era. Since the end of the Cold War, the United States has been expanding its economic and political power. More recently, it has begun to engage in increasingly unilateralist military policy… [Y]et despite these growing material capabilities, major powers such as China, France, Germany, India, and Russia have not responded with significant increases in their defense spending. Nor have they formed military coalitions to countervail US power, as the traditional balance of power theory would predict.
Towards the south and southwest lie the northern parts of the Central Uplands: the Weser Uplands and the Harz Mountains. Between these two lie the Lower Saxon Hills, a range of low ridges. The region in the northeast, the Lüneburg Heath (Lüneburger Heide), is the largest heathland area of Germany. In the Middle Ages, the town of Lüneburg was wealthy due to salt-mining and the salt trade. To the north the Elbe valley separates Lower Saxony from Hamburg, Schleswig-Holstein, Mecklenburg-Vorpommern, and Brandenburg. The left banks of the Elbe downstream Hamburg are known as the Altes Land (Old Country). Due to its gentle local climate and fertile soil, it is the state's largest area of fruit farming, its chief produce being apples. The modern state of Lower Saxony was created from parts of the British occupation zone after World War II by the merger of the State of Hanover with the three smaller free states of Braunschweig, Oldenburg and Schaumburg-Lippe on 1 November 1946. As most of the new state's territory consisted of the historic Kingdom of Hanover, Lower Saxony adopted its coat of arms and other symbols.
Sources: en.wikipedia.org
Artificially acquired passive immunity is a short-term immunization induced by the transfer of antibodies, which can be administered in several forms; as human or animal blood plasma, as pooled human immunoglobulin for intravenous (IVIG) or intramuscular (IG) use, and in the form of monoclonal antibodies (MAb). Passive transfer is used prophylactically in the case of immunodeficiency diseases, such as hypogammaglobulinemia. It is also used in the treatment of several types of acute infection, and to treat poisoning. Immunity derived from passive immunization lasts for only a short period of time, and there is also a potential risk for hypersensitivity reactions, and serum sickness, especially from gamma globulin of non-human origin. The artificial induction of passive immunity has been used for over a century to treat infectious disease, and before the advent of antibiotics, was often the only specific treatment for certain infections. Immunoglobulin therapy continued to be a first line therapy in the treatment of severe respiratory diseases until the 1930s, even after sulfonamide lot antibiotics were introduced.
Vantin (by Pfizer) in suspension or tablet form. Toraxim (by Delta Pharma Ltd., Bangladesh) Trucef (by Renata Limited, Bangladesh) Tricef (by Alkaloid Skopje, North Macedonia) Orelox (by Sanofi-Aventis) MAPDOX-CV: Combination cefpodoxime–clavulanic acid MONOTAX O (cefpodoxime)/MONOTAX CV (cefpodoxime–clavulanic acid) by Zydus Healthcare Ltd. ACXIME 200/CV (by Allencia Biosciences, India) POSTPOD-50 (cefpodoxime 50mg/5ml) by Laafon Galaxy Pharmaceuticals
Promising innovations relating to global challenges are reported: a viable real-time pathogen air quality (pAQ) sensor is demonstrated (10 July), a performant open source AI software for protein design (RFdiffusion) is introduced (11 July), metaresearchers show that AI trained with study-author-networks data could generate scientifically promising "alien" hypotheses that would likely not be considered otherwise (13 July), a study affirms that novel wearable more accessible TD-fNIRS headgear can be used instead of stationary fMRI with new findings about neurological effects of psychedelics (19 July), researchers demonstrate a DNA-sequencing-based technique to more effectively curb illegal sealife trade at warehouses and boats (19 July), a study provides an overview and living review of open source LLMs, assessing the levels of openness of their differentiated elements and reviewing the risks of relying on proprietary software or the importance of open source AI (19 July), news outlets start reporting on study from June demonstrating record solar-to-hydrogen efficiencies (20 July), multimodal biomedical Med-PaLM M is introduced (26 July).
===== Alkyl polyglucosides ===== Alkyl polyglycosides (APGs) are a class of non-ionic surfactants made from a sugar (like glucose) and a fatty alcohol. They are produced from renewable resources, possess a high biodegradability and mildness. For these reasons, they are widely used in detergents, cosmetics, and other applications. Decyl glucoside Lauryl glucoside Octyl glucoside
Sources: en.wikipedia.org
Molecular neuroscience is a branch of neuroscience that observes concepts in molecular biology applied to the nervous systems of animals. The scope of this subject covers topics such as molecular neuroanatomy, mechanisms of molecular signaling in the nervous system, the effects of genetics and epigenetics on neuronal development, and the molecular basis for neuroplasticity and neurodegenerative diseases. As with molecular biology, molecular neuroscience is a relatively new field that is considerably dynamic.
== In popular culture == The game of Tetris is a puzzle game in which blocks of 4 are adsorbed onto a surface during game play. Scientists have used Tetris blocks "as a proxy for molecules with a complex shape" and their "adsorption on a flat surface" for studying the thermodynamics of nanoparticles.
== Synthesis == Chymopapain is no longer used as a standard method to treat chronic low back pain because of its potential side effects. Therefore, there is no need to synthesize it artificially. In fact, the sale and distribution of this protein was discontinued in the US in 2003. Despite the huge amount of successful use to treat herniated disk disease, chymopapain use was discontinued not because of hazards or inadequacies but rather because it is no longer available due to a decision by its sole manufacturer to stop production. However, several studies have demonstrated different successful methods to extract and isolate the protease, which vary among authors. The most common procedure is the one described by Baines & Brocklehurst in 1979. In order to obtain the protein, Carica Papaya fruits are used, as chymopapain is found in its latex. The papayas should be just in the previous step before maturation, which implies an average diameter of 6–10 cm.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.